GlobeNewswire Clinical StudiesOriginal article
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ConferenceEnozertinibNeutral
AI Analysis
Summary
ORIC Pharmaceuticals announced three presentations at ESMO Congress 2026, including a poster on enozertinib from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC.
Clinical Trial Data
Phase
1b
Outcome Details
Poster presentation at ESMO Congress 2026
Importance:5/10
Sentiment:
0.20
ESMO CongressEnozertinibNSCLCPhase 1bPoster Presentation
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 20, 2026 12:30 PM